drugset / Trial / NCT05453487
Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine
Phase 4
Unknown
360 enrolled
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd. · collabChangchun Institute of Biological Products Co., Ltd. · collabGuizhou Center for Disease Control and Prevention · collabShaanxi Provincial Center for Disease Control and Prevention · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
Evaluation of immunogenicity and safety of inactivated COVID-19 vaccine (BBIBP-Cov) coadministered with rabies vaccine.
Timeline
- Start
- 2022-07-21
- Primary completion
- 2022-10-30
- Completion
- 2023-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BBIBP-CorV | Vaccine | — | — |
| Subject | Rabies vaccine | Vaccine | — | — |